Alaunos Therapeutics (TCRT) Enterprise Value (2009 - 2026)
Alaunos Therapeutics' (TCRT) quarterly Enterprise Value came in at -$354000.0 in Q1 2026, down 10.97% YoY from -$397626.8 in Q1 2025, and up 74.44% on a QoQ basis from -$1.4 million in Q4 2025.
Alaunos Therapeutics (TCRT) Enterprise Value (2009 - 2026) Analysis & Trends
Alaunos Therapeutics (TCRT) has 18 years of Enterprise Value data on file, last reported at -$354000.0 in Q1 2026.
- Quarterly Enterprise Value fell 10.97% year-over-year to -$354000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$354000.0 (down 10.97% YoY) and the FY2025 annual result came in at -$1.4 million, down 26.95% from the prior year.
- Enterprise Value climbed to -$354000.0 in Q1 2026, from -$1.4 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$319000.0 in Q1 2025 to a low of -$68.3 million in Q1 2022.
- A 5-year average of -$19.0 million and a median of -$4.1 million in 2024 frame the typical range for Enterprise Value.
- The widest YoY moves for Enterprise Value: up 92.3% in 2025, down 26.95% in 2025.
- Tracing TCRT's Enterprise Value over 5 years: stood at -$53.0 million in 2022, then surged by 88.56% to -$6.1 million in 2023, then surged by 82.0% to -$1.1 million in 2024, then retreated by 26.95% to -$1.4 million in 2025, then soared by 74.44% to -$354000.0 in 2026.
- The last three Enterprise Value figures came in at -$354000.0 (Q1 2026), -$1.4 million (Q4 2025), and -$1.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.12 Bn |
| 10 | Alaunos Therapeutics | 4.28 Mn | 4.16 Mn | - | -124,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -354,000.00 |
| Dec 31, 2025 | -1.39 Mn |
| Sep 30, 2025 | -1.94 Mn |
| Jun 30, 2025 | -2.88 Mn |
| Mar 31, 2025 | -319,000.00 |
| Dec 31, 2024 | -1.09 Mn |
| Sep 30, 2024 | -1.68 Mn |
| Jun 30, 2024 | -2.46 Mn |
| Mar 31, 2024 | -4.15 Mn |
| Dec 31, 2023 | -6.06 Mn |
| Sep 30, 2023 | -11.94 Mn |
| Jun 30, 2023 | -18.32 Mn |
| Mar 31, 2023 | -37.43 Mn |
| Dec 31, 2022 | -53.00 Mn |
| Sep 30, 2022 | -51.75 Mn |
| Jun 30, 2022 | -60.01 Mn |
| Mar 31, 2022 | -68.30 Mn |
| Dec 31, 2021 | -76.05 Mn |
| Sep 30, 2021 | -91.70 Mn |
| Jun 30, 2021 | -76.70 Mn |